Erlotinib accumulation in brain metastases from non-small cell lung cancer: Visualization by positron emission tomography in a patient harboring a mutation in the epidermal growth factor receptor

Journal of Thoracic Oncology

Volumn 6, Issue 7, 2011, Pages 1149-1151

  Stewart, David J ^a   Erasmus, Jeremy J ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; CISPLATIN; CYCLOPHOSPHAMIDE; DOXORUBICIN; EPIDERMAL GROWTH FACTOR RECEPTOR; ERLOTINIB; ERLOTINIB C 11; ETOPOSIDE; FLUOROURACIL; IRINOTECAN; TEMOZOLOMIDE; TRACER; UNCLASSIFIED DRUG;

BLOOD BRAIN BARRIER; BRAIN METASTASIS; BRAIN SCINTISCANNING; BRAIN TUMOR; CANCER ADJUVANT THERAPY; CANCER CHEMOTHERAPY; CANCER RESISTANCE; CANCER SURVIVAL; CELL PH; DIGESTIVE SYSTEM CANCER; DRUG ACCUMULATION; DRUG BRAIN LEVEL; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG HALF LIFE; DRUG PENETRATION; DRUG RECEPTOR BINDING; EDITORIAL; GENE DELETION; HUMAN; LUNG CANCER; LUNG NON SMALL CELL CANCER; MUTATIONAL ANALYSIS; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL;

EID: 79959911465     PISSN: 15560864     EISSN: 15561380     Source Type: Journal    
DOI: 10.1097/JTO.0b013e318223931f     Document Type: Editorial

References (22)

1. Weber B, Winterdahl M, Memon A, et al. Erlotinib accumulation in brain metastases from non-small cell lung cancer. Visualization by PET in a patient harboring a mutation in the epidermal growth factor receptor. J Thorac Oncol. 2011;6:1287-1289.
2. Ceresoli GL, Cappuzzo F, Gregorc F, et al. Gefitinib in patients with brain metastases from non-small-cell lung cancer: A prospective trial. Ann Oncol 2004;15:1042-1047. (Pubitemid 39089780)
3. Choong NW, Dietrich S, Seiwert TY, et al. Gefitinib response of erlotinib-refractory lung cancer involving meninges-role of EGFR mutation. Nat Clin Pract Oncol 2006;3:50-57. (Pubitemid 43108834)
4. Lai CS, Boshoff C, Falzon M, et al. Complete response to erlotinib treatment in brain metastases from recurrent NSCLC. Thorax 2006; 61:91. (Pubitemid 43106986)
5. Stewart DJ. A critique of the role of the blood-brain barrier in the chemotherapy of human brain tumors. J Neurooncol 1994;20:121-139. (Pubitemid 24309908)
6. Oh Y, Stewart DJ. Systemic therapy for lung cancer brain metastases: A rationale for clinical trials. Oncology 2008;22:168-178.
7. Stewart DJ, Richard MT, Hugenholtz H, et al. Penetration of VP-16 (etoposide) into human intracerebral and extracerebral tumors. J Neurooncol 1984;2:133-139. (Pubitemid 14050556)
8. Stewart DJ, Molepo M, Eapen L, et al. Cisplatin and radiation in the treatment of tumors of the central nervous system: Pharmacological considerations and results of early studies. Int J Radiat Oncol Biol Phys 1994;28:531-542. (Pubitemid 24020543)
9. Stewart DJ, Molepo M, Green RM, et al. Factors affecting platinum concentrations in human surgical tumour specimens after cisplatin. Br J Cancer 1995;71:598-604.
10. Shinaki T, Eguchi K, Sasaki Y, et al. A prognostic-factor risk index in advanced non-small-cell lung cancer treated with cisplatin-containing combination chemotherapy. Cancer Chemother Pharmacol 1992;30:1-6.
11. O'Connell JR, Kris MG, Gralla RJ, et al. Frequency and prognostic importance of pretreatment clinical characteristics in patients with advanced non-small-cell lung cancer treated with combination chemotherapy. J Clin Oncol 1986;4:1604-1614. (Pubitemid 17188927)
12. Nieder C, Grosu AL, Astner S, et al. Integration of chemotherapy into current treatment strategies for brain metastases from solid tumors. Radiat Oncol 2006;1:19.
13. Schuette W. Treatment of brain metastases from lung cancer: Chemotherapy. Lung Cancer 2004;45:S253-S257. (Pubitemid 39488196)
14. Oh Y, Taylor S, Bekele BN, et al. Number of metastatic sites is a strong predictor of survival in patients with nonsmall cell lung cancer with or without brain metastases. Cancer 2009;115:2930-2938.
15. Wolf W, Waluch V, Presant CA. Non-invasive 19F-NMRS of 5-fluorouracil in pharmacokinetics and pharmacodynamic studies. NMR Biomed 1998;11:380-387. (Pubitemid 28547373)
16. Presant CA, Wolf W, Waluch V, et al. Enhancement of fluorouracil uptake in human colorectal and gastric cancers by interferon or by high-dose methotrexate: An in vivo human study using noninvasive (19)F-magnetic resonance spectroscopy. J Clin Oncol 2000;18:255-261. (Pubitemid 30056412)
17. Mach J-P, Chatal J-F, Lumbroso J-D, et al. Tumor localization in patients by radiolabeled monoclonal antibodies against colon carcinoma. Cancer Res 1983;43:5593-5600.
18. Riva P, Moscatelli G, Paganelli G, et al. Antibody-guided diagnosis: An Italian experience on CEA-expressing tumours. Int J Cancer Suppl 1988;2:114-120. (Pubitemid 18077693)
19. Stewart DJ. Tumor and host factors that may limit efficacy of chemotherapy in non-small cell and small cell lung cancer. Crit Rev Oncol Hematol 2010;75:173-234.
20. Yeh HH, Ogawa K, Balatoni J, et al. Molecular imaging of active mutant L858R EGF receptor (EGFR) kinase-expressing non-small cell lung carcinomas using PET-CT. Proc Natl Acad Sci USA 2011;108:1603-1608.
21. Postmus PE, Smit EF. Chemotherapy for brain metastases of lung cancer: A review. Ann Oncol 1999;10:753-759. (Pubitemid 29367990)
22. Lee DH, Han JY, Kim HT, et al. Primary chemotherapy for newly diagnosed non-small cell lung cancer patients with synchronous brain metastases compared with whole-brain radiotherapy administered first: Result of a randomized pilot study. Cancer 2008;113:143-149.